MSCs, otherwise known as multipotent mesenchymal stromal cells, are being examined for the treatment of autoimmune disease (AD) on the basis of their in vitro antiproliferative properties, efficacy in animal models, apparent low acute toxicity and the early positive anecdotal outcomes in human acute GVHD. Phase I/II clinical trials are underway in Crohn's disease and multiple sclerosis (MS) and are being planned for systemic lupus erythematosus (SLE), systemic sclerosis (SSc), systemic vasculitis and other AD. Open issues include patient selection, disease stage and activity, MSC source and expansion and long-term safety. Multidisciplinary groups are collaborating to ensure maximal use of available resources to establish the place, if any, of MSC in the treatment of AD.
展开▼
机译：正在根据其体外抗增殖特性，在动物模型中的功效，明显的低急性毒性和在人类急性中的早期阳性轶事结果，对MSC（也称为多能间充质基质细胞）进行检查以治疗自身免疫性疾病（AD）。 GVHD。 I / II期临床试验正在进行克罗恩病和多发性硬化症（MS），并计划用于系统性红斑狼疮（SLE），系统性硬化症（SSc），系统性血管炎和其他AD。尚待解决的问题包括患者选择，疾病分期和活动，MSC来源和扩展以及长期安全性。多学科小组正在合作以确保最大程度地利用可用资源来建立MSC在AD治疗中的位置（如果有）。
展开▼
